Upgrade to SI Premium - Free Trial

Navidea Biopharma (NAVB) Misses Q3 EPS by 1c

November 4, 2015 7:37 AM

Navidea Biopharma (NYSE: NAVB) reported Q3 EPS of ($0.05), $0.01 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $3.98 million versus the consensus estimate of $2.78 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

Categories

Earnings

Next Articles